Desperate pancreatic cancer patients offered experimental Two-Drug combo
NCT ID NCT07175389
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial will test a combination of two drugs—JDB153 (taken as a pill) and serplulimab (given by IV)—in 10 people with advanced pancreatic cancer that has not responded to standard treatments. The main goals are to check safety and see if the drugs can shrink tumors. Because it is a small, early study, it is too soon to know if this approach will work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JDB153 (oral drug) and serplulimab (intravenous immunotherapy)
- What this could lead to
- If it works, this could point toward a new treatment option for pancreatic cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a very early, small trial (only 10 people) testing safety first. The combination may not shrink tumors or improve survival, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.